Market Currents
More on Arena Pharmaceuticals (ARNA): Q3 beats on a per share basis but comes up short on...
-
Tuesday, November 6, 2012, 4:38 PM ETMore on Arena Pharmaceuticals (ARNA): Q3 beats on a per share basis but comes up short on revenue. Separately, the company announced that it had granted Ildong Pharmaceutical exclusive rights to market and distribute its weight-loss drug Belviq in South Korea, subject to regulatory approval of BELVIQ by the Korea Food and Drug Administration. Shares +1.6% AH.
Other date
Latest Earnings Articles
This news story has 8 comments:
seems to be winner in the long terms.
Have a nice day for all investors.
Paul
Let's dig a little bit deeper into the cc of Nov.6 please.
I have a little knowledge about the market. I have been with MM for the past 8 to 10 years, going thru the trials of some stocks that are still eye sores. Knowing that the stupid bug got me in RE:Diamond Fields. Another of the would A shoulda stocks. I watched the ship leave the shore and waved bye bye to a lot of money. Thanks for ARENA. Now I hope I will be able to get back in at a good price.
I was able to recoup a lot. I have been disabled for the past 20 years so I have to push the pain aside with medication, but It is a Long time squatter that will never leave.